E89R
TEAS SECTION 8 & 9 RECEIVED
07/07/2026
Back to search
Official data from USPTO
SAMIRNA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SAMIRNA
ST13
US500000086287682Class
1, 5, 10, 42
Filing
86287682
Registration
5052167
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
07/09/2026
Trademark type
Word
Nice classes
1, 5, 10, 42
Filing date
05/21/2014
Registration date
10/04/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/05/2022
Last transaction
07/09/2026
Responsible office
United States Patent and Trademark Office
Status code
704
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Daejeon, KR
Examiner
KING, CHRISTINA B
Law office
L90
Holders and representatives
Holders
B. C. (pessoa física)
B. C. (pessoa física)
Representatives
Jun-Hwa Jeong RABIN & BERDO, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Diagnostic preparations for research use; Reagents for scientific research use; Chemicals for laboratory analysesother than for medical usechemicals for use in biotechnological product development; Chemicals for pharmaceutical purposesfor use in the manufacture of drugs and medicines; Chemicals for the manufacture of medical products in the nature of pharmaceutical preparations; Biochemicalsbiochemical reagents used for non-medical purposes; Chemical preparations for the manufacture of medical products
Class 5
Pharmaceutical preparations for the treatment of cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies; Biological preparations for the treatment of cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies; Medicated vaccines and serums for treatment of cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies; Capsules sold empty for pharmaceutical purposes for the treatment of cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies; Microspheres containing pharmaceutical preparationsfor treating cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies; Preparations and substances for facilitating delivery of pharmaceutical preparationsdrug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Carriers for drug deliverydrug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Peptides for drug deliverydrug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; Pharmaceutical preparations applied pharmaceutical drug delivery systemelixirs for the treatment of cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies and a nanoparticle carrier for transferring siRNA in the cell or peptide; Chemical reagents for medical use; Pharmaceutical preparations for drug delivery into cells; Drug delivery formulationscompositions consisting of nanoparticle for transferring siRNA in the cell or peptides; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purpose; Pharmaceutical preparations and substances for facilitating drug delivery in the form of nanoparticle for transferring siRNA in the cell or peptide for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing RNA for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing DNA for use in medical treatment via inhibition of gene expression
Class 10
Drug delivery system; Implantable drug syringes for drug delivery devices; Implantable drug delivery pumps for drug delivery devices; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Injection device for pharmaceuticals; Microspheresunilaminar and bilaminar spherical particles comprising hydrophilic and hydrophobic polymers with diameters in the nanometer range used as a means for drug delivery for treating cancertumorrespiratory diseaseimmunization diseaseskin diseaseviral diseaseallergies
Class 42
Pharmaceutical products research; Pharmaceutical products development; Research for medical products; Crude medicines research; Research and development of biotechnology for others; Quality controlquality control of target gene expression activity with siRNA; Biotechnology research
Publications
History of USPTO decisions and trademark events.
44 publications found
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/04/2025
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
10/05/2022
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
10/05/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/04/2022
ES8R
TEAS SECTION 8 RECEIVED
04/26/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/04/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
10/04/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/19/2016
PUBO
PUBLISHED FOR OPPOSITION
07/19/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/29/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/15/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/08/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
06/08/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/08/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
06/08/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/08/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/21/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/20/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/20/2016
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
11/23/2015
GPRA
PRIORITY ACTION E-MAILED
11/23/2015
CPRA
PRIORITY ACTION WRITTEN
11/23/2015
DMCC
DATA MODIFICATION COMPLETED
11/16/2015
ALIE
ASSIGNED TO LIE
11/16/2015
DOCK
ASSIGNED TO EXAMINER
11/09/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/23/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/23/2015
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/23/2015
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
08/21/2015
GNSI
INQUIRY TO SUSPENSION E-MAILED
08/21/2015
CNSI
SUSPENSION INQUIRY WRITTEN
08/21/2015
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/06/2015
GNSL
LETTER OF SUSPENSION E-MAILED
02/06/2015
CNSL
SUSPENSION LETTER WRITTEN
02/06/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/05/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/04/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/04/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/04/2014
GNRT
NON-FINAL ACTION E-MAILED
08/04/2014
CNRT
NON-FINAL ACTION WRITTEN
08/04/2014
DOCK
ASSIGNED TO EXAMINER
08/04/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/04/2014
NWAP
NEW APPLICATION ENTERED
05/24/2014
Continuous trademark protection
Get notified about every new filing that threatens SAMIRNA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.